Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Half of Fosun Pharma’s Hong Kong IPO Will Fund Acquisitions

publication date: Oct 17, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Fosun Pharma’s $600 million Hong Kong IPO remains on track for completion this month, as the bankers have begun taking orders. Pricing will be on October 23, and the stock will begin trading on October 30. Half of the $600 million proceeds will be allocated to acquisitions, according to the company, which has a well-earned reputation as one of China pharma’s most active dealmakers. More details....

Stock Symbol: (SHA: 600196)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors